COOLOGICS

About COOLOGICS

Coologics is a company focused on providing the first drug-free, faster, and more effective treatment for vaginal infections. Their clinically proven, safe, tampon-like device offers immediate symptom relief and aims to address issues like antibiotic resistance, recurrent infections, preterm births, and significant productivity losses due to vaginal infections. The solution was invented by a female OB/GYN who experienced these challenges personally.

Products & Services

Vlisse:A patented, non-drug treatment for yeast and bacterial vaginal infections using controlled cooling technology. It offers faster and more effective treatment with immediate symptom relief, without the use of chemicals.

Specialties

Vaginal Infection Treatment Drug-Free Medical Devices Controlled Cooling Technology Women's Health

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 3000000 MR: - FA: over $3 million FAN: 3000000	D: 2025-04-23 FD: 2025-04-23	4 investors

Seed Latest

2025-04-23

$3.0M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

K

Kim Langdon, MD

N

Nicole Williams, MD

K

Keith Aqua, MD

C

Cynthia Pritchard, PHD

S

Sean McKibben

R

Rich Mazzola

View 11 more team members with Pro

Unlock Full Team Directory

Recent News

COOLOGICS Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised